138 related articles for article (PubMed ID: 38014717)
21. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma.
Josyula S; Pont MJ; Dasgupta S; Song X; Thomas S; Pepper G; Keane-Candib J; Stevens-Ayers TL; Ochs HD; Boeckh MJ; Riddell SR; Cowan AJ; Krantz EM; Green DJ; Hill JA
Transplant Cell Ther; 2022 Jun; 28(6):304.e1-304.e9. PubMed ID: 35288345
[TBL] [Abstract][Full Text] [Related]
22. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
23. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
24. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Sanchez E; Li M; Kitto A; Li J; Wang CS; Kirk DT; Yellin O; Nichols CM; Dreyer MP; Ahles CP; Robinson A; Madden E; Waterman GN; Swift RA; Bonavida B; Boccia R; Vescio RA; Crowley J; Chen H; Berenson JR
Br J Haematol; 2012 Sep; 158(6):727-38. PubMed ID: 22804669
[TBL] [Abstract][Full Text] [Related]
25. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
Pillarisetti K; Powers G; Luistro L; Babich A; Baldwin E; Li Y; Zhang X; Mendonça M; Majewski N; Nanjunda R; Chin D; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Sep; 4(18):4538-4549. PubMed ID: 32956453
[TBL] [Abstract][Full Text] [Related]
26. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
[TBL] [Abstract][Full Text] [Related]
27. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.
Salem DA; Maric I; Yuan CM; Liewehr DJ; Venzon DJ; Kochenderfer J; Stetler-Stevenson M
Leuk Res; 2018 Aug; 71():106-111. PubMed ID: 30053652
[TBL] [Abstract][Full Text] [Related]
28. The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.
Xu Y; Mao X; Que Y; Xu M; Li C; Almeida VDF; Wang D; Li C
BMC Cancer; 2023 Feb; 23(1):123. PubMed ID: 36750969
[TBL] [Abstract][Full Text] [Related]
29. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
30. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
31. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
[TBL] [Abstract][Full Text] [Related]
32. γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not.
Lessard CB; Rodriguez E; Ladd TB; Minter LM; Osborne BA; Miele L; Golde TE; Ran Y
Alzheimers Res Ther; 2020 May; 12(1):61. PubMed ID: 32430033
[TBL] [Abstract][Full Text] [Related]
33. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Da Vià MC; Dietrich O; Truger M; Arampatzi P; Duell J; Heidemeier A; Zhou X; Danhof S; Kraus S; Chatterjee M; Meggendorfer M; Twardziok S; Goebeler ME; Topp MS; Hudecek M; Prommersberger S; Hege K; Kaiser S; Fuhr V; Weinhold N; Rosenwald A; Erhard F; Haferlach C; Einsele H; Kortüm KM; Saliba AE; Rasche L
Nat Med; 2021 Apr; 27(4):616-619. PubMed ID: 33619368
[TBL] [Abstract][Full Text] [Related]
34. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
35. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
36. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
Bera TK
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003418
[TBL] [Abstract][Full Text] [Related]
37. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
[TBL] [Abstract][Full Text] [Related]
38. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.
Bilich T; Nelde A; Bauer J; Walz S; Roerden M; Salih HR; Weisel K; Besemer B; Marcu A; Lübke M; Schuhmacher J; Neidert MC; Rammensee HG; Stevanović S; Walz JS
Blood Cancer J; 2020 Feb; 10(2):24. PubMed ID: 32111817
[TBL] [Abstract][Full Text] [Related]
39. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ju S
Cell Biochem Funct; 2016 Mar; 34(2):104-10. PubMed ID: 26914861
[TBL] [Abstract][Full Text] [Related]
40. Evidence For and Against a Pathogenic Role of Reduced γ-Secretase Activity in Familial Alzheimer's Disease.
Jayne T; Newman M; Verdile G; Sutherland G; Münch G; Musgrave I; Moussavi Nik SH; Lardelli M
J Alzheimers Dis; 2016 Apr; 52(3):781-99. PubMed ID: 27060961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
